Highlights CytoDyn Inc.

Equities

CYDY

US23283M1018

Market Closed - OTC Markets Other stock markets 20:59:31 15/05/2024 BST			5-day change	1st Jan Change
0.165 ^USD	-1.84%		+6.87%	-15.38%

04-15	CytoDyn Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	CI
03-05	Transcript : CytoDyn Inc. - Special Call

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CytoDyn Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	04-15	CI
CytoDyn Inc. Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma	02-01	CI
CytoDyn Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	01-16	CI
CytoDyn Inc. Reports Earnings Results for the First Quarter Ended August 31, 2023	23/10/23	CI
CytoDyn Inc. Reports Earnings Results for the Full Year Ended May 31, 2023	14/09/23	CI
CytoDyn Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2023	10/04/23	CI
CYTODYN INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	09/01/23	AQ
CytoDyn Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2022	09/01/23	CI
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues	28/10/22	CI
CYTODYN INC. : Change in Directors or Principal Officers (form 8-K)	19/10/22	AQ
CytoDyn Inc. Announces Board Changes	19/10/22	CI
CytoDyn Inc. Reports Earnings Results for the First Quarter Ended August 31, 2022	11/10/22	CI
CytoDyn Inc. Reports Earnings Results for the Full Year Ended May 31, 2022	15/08/22	CI
CytoDyn Inc. Announces Preclinical Study in Nonhuman Primates That Will Evaluate the Potential Use in HIV of a Gene Therapy Based on the Experimental Monoclonal Antibody Leronlimab	11/07/22	CI
CytoDyn Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2022	11/04/22	CI
CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program	30/03/22	CI
CytoDyn Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2021	10/01/22	CI
Regnum Signs Assignment and Assumption Agreement with CytoDyn and SevenScore Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV	10/01/22	CI
CytoDyn Inc. Announces Research Paper Published Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 from Heavily Treatment Experienced Subjects	10/01/22	CI
CytoDyn Inc. Announces Positive Results from the 350 Mg Weekly Dose of Its Phase 2 NASH Clinical Trial	05/01/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CytoDyn Inc.

Equities

CYDY

US23283M1018

Highlights

Filters